Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
21.29 USD
831.57 M USD
2.19 B USD
61.32 M
About argenx SE
Sector
Industry
CEO
Tim van Hauwermeiren
Website
Headquarters
Amsterdam
Founded
2008
ISIN
US04016X1019
FIGI
BBG00GHB88X9
argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. It operates through the following geographical segments: United States, Japan, EMEA, and China. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Amsterdam, the Netherlands.
Related stocks
Argenx (ARGX) AnalysisCompany Overview: Argenx NASDAQ:ARGX is making significant strides in the field of autoimmune treatments, especially following the FDA approval of VYVGART Hytrulo for chronic inflammatory demyelinating polyneuropathy (CIDP) on June 21st. This approval not only enhances Argenx's product portfolio b
Argenx Lead as Chugai's Muscle Disease Treatment DisappointsIn a whirlwind of market reactions, biotech stocks Argenx ( NASDAQ:ARGX ) and Immunovant ( NASDAQ:IMVT ) emerged as frontrunners on Thursday, propelled by disappointing results from Japanese rival Chugai Pharmaceutical. The contrast in fortunes underscores the high stakes and volatile nature of the
Breakout trade in ARGXArgenx is another biotech stock setting up in a textbook breakout pattern.
Shares traded up through resistance Monday morning on good volume, but the move was ultimately held back by a nasty overall market.
ARGX still held up well, and will likely continue its advance higher.
$ARGX with a Bearish outlook following its earnings #Stocks The PEAD projected a Bearish outlook for $ARGX after a Positive Under reaction following its earnings release placing the stock in drift D.
ARGX Bullish Trade Setup Looking to place some longs on ARGX. Argenx SE operates as a biotechnology company. The Company develops antibody based therapies for the treatment of severe autoimmune diseases and cancer. argenx serves customers in the Netherlands and Belgium.n top 10: 10 8 25.0% 6 (0.35%) 6 (0.35%) 0.0%
Funds Hol
Will ARGX break out ascending channelWill Argenx be Wall streets next Biotech unicorn? I am extremely bullish!
Biotech is booming business. Monoclonal antibodies are revolutionizing pharma industry.
Again great news for Argenx.
01feb2021
launches new global offering to raise funds after 'Go' decisions for CIDP treatment trials
ARGX Buy Signal To Watch .After forming the gap at the market open , NASDAQ:ARGX has succeeded to close above the Red Line around the 206.5 .
IF it succeeds today or in an upcoming day to close with bullish strength considerably above the green line at around the 217 mark ,I think It is likely to continue up to around th
argenx Announces Positive Topline Results from Phase 3 ADAPT TriARGX: argenx SE
2020-05-26 01:00:00
argenx Announces Positive Topline Results from Phase 3 ADAPT Trial of Efgartigimod in Patients with Generalized Myasthenia Gravis
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Curated watchlists where ARGX is featured.
